Guggenheim analyst Brad Canino raised the firm’s price target on Nuvalent (NUVL) to $155 from $125 and keeps a Buy rating on the shares. The positive neladalkib pivotal data lead the firm to “fully de-risk” its second-to-third line ALK+ NSCLC odds of success estimate and increase its first-line odds to 75%, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: